AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01623427 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No vacuum
Description: Except for the vacuum, the wound dressing for the umbilical port site will be the same. No vacuum will be applied to the wound dressing of this group
Study NCT03580304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical load
Description: The physical load of an industrial task will be simulated during this intervention. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Before and after the trial, mental fatigue will be determined by questionnaires and a cognitive stroop task (10 min)
Study NCT03379584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-CD48A
Description: Intravenous (IV) infusion on days 1, 8, and 15 of a 28-day cycle
Study NCT02462057 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Email message regarding the HealthyFood benefit
Study NCT03580304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive load
Description: The cognitive load of an industrial task will be simulated in this intervention. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Before and after the trial, mental fatigue will be determined by questionnaires and a cognitive stroop task (10 min)
Study NCT01070862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide, Dexamethasone
Description: Thalidomide 200 mg/d for 3 months, Dexamethasone 40 mg/d D1-D4 and D14-D17 for 28d-3 cycles
Study NCT01070862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristin , Adriamycin, Dexamethasone = VAD
Description: Vincristin 0.4 mg/d continUous IV infusion D1-D4, Adriamycin 9 mg/m2 continuous IV infusion D1-D4, Dexamethasone 40 mg/d oral D1-D4 and D15-D18 for 2 first cycles, D1-D4 for the 3d cycle
Study NCT01070862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide, melphalan, endoxan, dexamethasone (MCDex-Thal)
Description: Thalidomide : 200 mg/d at bedtime for 3 months , melphalan: 6 mg/m2 oral D1-D4, endoxan 600 mg/m2 IV D1, dexamethasone 40 mg/d oral D1-D4 for 28-d 4 cycles
Study NCT01070862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melphalan, endoxan, dexamethasone (MCDex)
Description: melphalan: 6 mg/m2 oral D1-D4, endoxan 600 mg/m2 IV D1, dexamethasone 40 mg/d oral D1-D4 for 28-d 4 cycles
Study NCT01070862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide, Dexamethasone
Description: Thalidomide 200 mg/d on every other 3 months Dexamethasone 40 mg/d D1-D4, D30-D34,D60-D64, D90-D94
Study NCT02567552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous progesterone
Description: subcutaneous progesterone 25 mg/day
Study NCT02567552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular progesterone
Description: intramuscular progesterone 50 mg/day
Study NCT02123628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: duration of the antibiotic therapy
Study NCT03302520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoMax, BioAlpha Inc, Seong-nam, Korea
Description: CaO-SiO2-P2O5-B2O3 glass ceramics spacer
Study NCT03302520 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEEK cage
Description: PEEK cage
Study NCT05656989 — intervention group
Intervention type: OTHER
Intervention: Periodontal clinical measurements and GCF sampling
Description: Periodontal clinical parameters measurements probing depth (PD), clinical attachment loss (CAL), the dichotomous recording (present/absent) of bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were recorded at six sites (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual) per tooth, except the third molars using a manual periodontal probe. A sterile paper strip was gently placed into the gingival sulcus/periodontal pocket until mild resistance was sensed and left in place for 30 seconds.
Study NCT02168426 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Guardix
Description: Applying 6g of guardix during abdominal surgery
Study NCT02168426 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Seprafilm
Description: Applying 1 sheet of seprafilm during abdominal surgery
Study NCT00596180 — intervention group
Intervention type: DRUG
Intervention: HBOT
Description: total body exposure to greater than atmospheric pressure oxygen
Study NCT03243266 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CBC/Diff Reference Interval
Description: Results will not be used to manage patients
Study NCT04561674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of web-based patient education
Description: Web-Based Patient Education on Colostomy and Ileostomy (WBPECI) was developed in accordance with the principles of the ADDIE instructional design. The web-based education was designed in line with these learning objectives determined. The content of the website was developed in light of the opinions sought from five subject experts. The WBPECI content includes a total of 7 videos, 1 animation with sound, 1 forum and 1 consultation page
Study NCT03150667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor in patients with CKD presenting with ACS.
Study NCT03150667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel in patients with CKD presenting with ACS.
Study NCT03206255 — intervention group
Intervention type: PROCEDURE
Intervention: 3 doses of HPV 16/18 bivalent vaccine
Description: Participants have received 60μg of HPV 16/18 bivalent vaccine according to the standard 3-dose schedule (0,1,6 months)
Study NCT03206255 — intervention group
Intervention type: PROCEDURE
Intervention: 2 doses of HPV 16/18 bivalent vaccine
Description: Participants have received 60μg of HPV 16/18 bivalent vaccine according to an alternative 2-dose schedule (0,6 months)
Study NCT00003046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interleukin-12
Description: Intraperitoneal over 30 minutes once weekly for 4 weeks, repeats every 4 weeks for up to 6 courses
Study NCT01152450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium 2.5 µg b.i.d
Description: 2.5 µg (two actuations of 1.25 µg) delivered via Respimat® inhaler
Study NCT01152450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: N/A (two actuations of placebo) delivered via Respimat® inhaler
Study NCT01152450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 µg q.d.
Description: 5 µg (two actuations of 2.5 µg) delivered via Respimat® inhaler
Study NCT02841527 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Band
Description: Surgical intervention in which a band is inserted around the top of the stomach to reduce its size.
Study NCT04405804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine 5Mg Tab
Description: Initial dose of ivabradine will be:~0.02 mg/kg/dose twice daily in patients between 6-12 months 0.05 mg/kg/dose twice daily in patients between 1-3 years and 3-18 years with a weight \< 40 kg 2.5 mg/day in patients between 3-18 years with weight > 40 kg During titration phase, the dose may be increased, maintained, reduced or discontinued in accordance with titration rules. The titration rules will be adjusted on the basis of age subset and of each patient's evaluation during the titration phase, whether or not the target heart rate is reached (HR ≥ 20% compared to baseline HR) and whether or not are present bradycardia (HR should be greater than predefined by a HR threshold per age subset) and/or bradycardia-related symptoms.~Maximum dose to be reached will be:~0.2 mg/kg/dose twice daily in patients between 6-12 months 0.3 mg/kg/dose twice daily in patients between 1-3 years and 3-18 years with a weight \< 40 kg 15 mg/day in patients between 3-18 years, weight > 40 kg
Study NCT04146272 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid Mermaid Current
Description: The current hearing aid used to treat hearing loss.
Study NCT04146272 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid Mermaid New
Description: The new hearing aid used to treat hearing loss with an upgraded feedback cancellation system.
Study NCT01257165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol
Description: 50 mg per 70 kg body weight, given orally as a single dose
Study NCT01257165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo pill
Description: Placebo pill identical to zopiclone pill, given orally as a single dose
Study NCT01257165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Placebo pill identical to zopiclone pill, given orally as a single dose
Study NCT01257165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pill
Description: Placebo pill identical to zopiclone pill, given orally as a single dose
Study NCT01257165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Placebo drink, given orally as a single dose
Study NCT01257165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo drink
Description: Placebo drink, given orally as a single dose
Study NCT01982760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDAVP
Description: Patients Receiving DDAVP prior to operation
Study NCT02726555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Red yeast rice and atorvastatin
Description: Participants will receive 2 capsules of 300mg red yeast rice and 2 capsules of 10mg atorvastatin for 24 weeks.
Study NCT02726555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin alone
Description: Participants will receive 2 capsules of placebo and 2 capsules of 10mg atorvastatin for 24 weeks.
Study NCT02485795 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: This study will evaluate the impact of genetic testing information on medical regimen plans and whether this information results in benefits to patient care.
Study NCT02651402 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FRIENDS for Life
Description: Friends for Life (FRIENDS): FRIENDS, a GCBT program, is an effective program for the prevention and treatment of anxiety disorders in children evidenced by a meta-analysis on school-based interventions for at-risk and clinically anxious youth. FRIENDS was developed based on the view that anxiety is a tripartite construct involving physiological, cognitive, and behavioral components. Core Intervention components: Experts in CBT for childhood anxiety disorders have identified 5 essential components: psychoeducation, somatic management skills training, cognitive restructuring, exposure methods, and contingency management. The FRIENDS protocol consists of 10 weekly sessions and two booster sessions. We included the booster sessions in the regular protocol for a total of 12 sessions.
Study NCT02651402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted FRIENDS
Description: Adapted Friends (aFRIENDS): We conducted planned adaptations to the FRIENDS protocol based on our collective experience with the protocol and qualitative data (focus group and interviews). We followed procedures developed by Lee and colleagues, including surveying service providers and trainers regarding the appropriateness of FRIENDS for the target population. Changes were made to the language (idioms, metaphors, words), cultural fit (cultural values), methods (session length, number of sessions), activities (in-session practices), which resulted in additions and substitutions in these areas while maintaining the 5 essential components of the treatment. aFRIENDS is a briefer (8-session) and more engaging and culturally-sensitive protocol than FRIENDS.
Study NCT02651402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Train-the-Trainer
Description: Train the Trainer (TT): agency supervisors are trained to conduct effective supervision (one initial training and 2 booster sessions), and then go on to train intervention therapists.
Study NCT02651402 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Train-the-Trainer
Description: Train the Trainer (TT): agency supervisors are trained to conduct effective supervision (one initial training and 2 booster sessions), and then go on to train intervention therapists.
Study NCT02651402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Train-the-Trainer Plus
Description: Train the Trainer Plus (TT+): a modified train-the-trainer approach by which supervisors receive training plus extended on-going consultation on conducting effective supervision with intervention therapists.
Study NCT02992665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ca Ionophore A23187
Description: Sibling oocytes are to be randomized to artificially activated using Calcium ionophore in cases with severely compromized semen parameters
Study NCT02992665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is used to control Ca ionophore group
Study NCT01386216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magellan®
Description: Autologous Bone Marrow Cell Concentrate Prepared Using the Magellan System to be injected into the ischemic muscle tissue at 0.5 cc/injection for a total of 12-20 cc.
Study NCT00662038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pirfenidone
Description: Pirfenidone, 2403 mg/d, administered as 801-mg doses, three times daily.
Study NCT00070122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT00070122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally
Study NCT01606189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW-1000-02
Description: Contains delta-9-tetrahydrocannabinol (THC) (25 mg/ml) and cannabidiol (CBD) (25mg/ml) as extract of Cannabis sativa L, with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg and CBD 2.5 mg). The maximum daily exposure was set at 48 actuations per day.
Study NCT01606189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW-2000-02
Description: Contains THC (25 mg/ml) as extract of Cannabis sativa L, with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg). The maximum daily exposure was set at 48 actuations per day.
Study NCT01606189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contains peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum daily exposure was set at 48 actuations per day.
Study NCT02731404 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: HFJV ventilation
Description: The investigators used the Perkins tonometer for monitoring intra-ocular pressure. Evaluation of intra-ocular pressure was done before induction of anesthesia, end of induction, during surgery and at the end of surgery.
Study NCT02731404 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: IPPV ventilation
Description: The investigators used the Perkins tonometer for monitoring intra-ocular pressure. Evaluation of intra-ocular pressure was done before induction of anesthesia, end of induction, during surgery and at the end of surgery.
Study NCT03431519 — intervention group
Intervention type: PROCEDURE
Intervention: VP
Description: Percutaneous Injection of Strontium Containing Hydroxyapatite versus Polymethacrylate plus Short Segment Pedicle Screw Fixation
Study NCT03691584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-6076
Description: The dose planned to be administered in this study is an iv infusion of 30 mg TP 6076 q24h for 4 consecutive days (starting on Day 1 and ending on Day 4).
Study NCT03691584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage
Description: Subjects will be randomized to undergo a BAL at a single time point: either 2, 4, 8, or 24 hours after the start of the final TP-6076 iv infusion on Day 4.
Study NCT04768790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multidisciplinary program
Description: multimodal exercises to improve, through gradual exposure, cervical mobility, postural control and strengthening of the cervical muscles; stabilization techniques for the deep neck muscles; task-oriented exercises maintaining the activation of the deep spinal muscle. Under the supervision of a psychologist, the subjects will also be involved in cognitive-behavioral therapy aimed at modifying the fear of movement (kinesiophobia) and the maladaptive behavior of the disease. Ergonomic consultancy.
Study NCT02841527 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Bypass
Description: Surgical intervention where a small pouch is made in the top of the stomach and a loop of bowel connected to this pouch to bypass the rest of the stomach.
Study NCT02841527 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve Gastrectomy
Description: Surgical intervention which reduces the size of the stomach by about 75%, creating a narrow tube. It is done by stapling down the stomach and removing the remainder of the stomach.
Study NCT00006389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bryostatin 1
Description: Given IV
Study NCT00006389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT04768790 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General program
Description: exercises for muscle strengthening, regional stretching and spinal mobilization. Ergonomic consultancy.
Study NCT01133509 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gardasil
Description: 0.5ml IM for three doses, Second and third dose to be given at 2 months and 6 months
Study NCT01643395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vertebroplasty
Description: Vertebroplasty consists in the injection of cement (PMMA) in the damaged vertebral body to prevent further collapse
Study NCT01643395 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conservative therapy
Description: The study is a prospective, randomized trial comparing conservative treatment (brace) and vertebroplasty in acute (less than 15 days after trauma) traumatic vertebral compression fracture (VCF) type A according Magerl classification.
Study NCT05465694 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2-minute-time interval of per oral 24% sucrose
Description: Experiment began with a five-minute observation period of all outcome measures while infant was resting in an incubator. Later, attendant nurse gave 1 ml of 24% sucrose solution on neonate's tongue. In the 2-two minute-time interval prior to heel lance intervention, following two minutes of waiting period, heel lance procedure was applied to infant's foot. In no time interval of sucrose given immediately prior to heel lance intervention, attendant nurse performed heel lance procedure immediately after giving 1 ml of 24% sucrose solution sucrose on tongue. Infant's facial actions and heart rate, and oxygen saturation were recorded by using two video cameras. Recording was carried out by a nurse during whole procedure. After collecting data, researcher watched videos separately and scored them by using PIPP-R. Measurement of study outcome relied on data collection strategies: Neonatal close-up video recording of infant facial actions, pulse oximeter, observation for adverse events.
Study NCT05465694 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no time interval of per oral 24% sucrose
Description: no time interval of per oral 24% sucrose
Study NCT03459495 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic ultrasound
Description: Patients in the ultrasound group will be administered to the posterior neck region for 5 minutes in pulsed mode (pulse rate 1: 1) at 1 MHz, 1.5 W / cm2. The treatment will be done 5 days a week for a total of 10 days
Study NCT03459495 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo ultrasound
Description: When the ultrasonic device is in the closed position, the ultrasonic probe will be applied for 5 minutes in the posterior neck region of the patients. The treatment will be done 5 days a week for a total of 10 days.
Study NCT03460717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Field Stimulation by Thermal Micro-Cautery
Description: The most painful points over the knee received an intense heat by a metal rod for 0.5 seconds.
Study NCT06417645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fixed propofol infusion 15 mg/kg/h until 1% BSR (burst suppression ratio)
Description: after a slow induction with propofol to loss of consiousness (LOC), we proceed to give remifentanil TCI and rocuronium and intubate the patient. After 5 min we infuse 15 mg/kg/h until 1%BSR observe in the BIS monitor. Then we reduce the TCI LOC predicted concentration.
Study NCT04146272 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Power Hearing Aid Current
Description: The current power hearing aid used to treat strong hearing loss.
Study NCT04146272 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Power Hearing Aid New
Description: The new power hearing aid used to treat strong hearing loss with an upgraded feedback cancellation system.
Study NCT00006389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies